Association Between Doses of Levonorgestrel Intrauterine Systems and Subsequent Use of Psychotropic Drugs in France.

Roland, Noémie; Baricault, Bérangère; Weill, Alain; Bouillon, Kim; Dray-Spira, Rosemary; Duranteau, Lise; Zureik, Mahmoud

Roland, Noémie; Baricault, Bérangère; Weill, Alain; Bouillon, Kim; Dray-Spira, Rosemary; Duranteau, Lise; Zureik, Mahmoud.

Afiliação

Roland N; EPI-PHARE (ANSM/CNAM), Saint-Denis, France.
Baricault B; EPI-PHARE (ANSM/CNAM), Saint-Denis, France.
Weill A; EPI-PHARE (ANSM/CNAM), Saint-Denis, France.
Bouillon K; EPI-PHARE (ANSM/CNAM), Saint-Denis, France.
Dray-Spira R; EPI-PHARE (ANSM/CNAM), Saint-Denis, France.
Duranteau L; Department of Medical Gynecology, Le Kremlin Bicêtre Hospital, Paris, France.
Zureik M; EPI-PHARE (ANSM/CNAM), Saint-Denis, France.

JAMA ; 329(3): 257-259, 2023 01 17.

Article em En | MEDLINE | ID: mdl-36548007

This matched-cohort study uses data from the French National Health Insurance database to assess whether a 19.5-mg levonorgestrel intrauterine system, vs a 52-mg system, is associated with increased use of antidepressant, hypnotic, and anxiolytic medications.

Assuntos

Dispositivos Intrauterinos Medicados; Levanogestrel; Psicotrópicos; França; Levanogestrel/administração & dosagem; Levanogestrel/efeitos adversos; Psicotrópicos/uso terapêutico; Dispositivos Intrauterinos Medicados/efeitos adversos; Humanos; Feminino

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psicotrópicos / Levanogestrel / Dispositivos Intrauterinos Medicados Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans País como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google